Cart 0
Eosinophilic Esophagitis Pipeline Analysis 2018 (Q1)

Eosinophilic Esophagitis Pipeline Analysis 2018 (Q1) – Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments

  • $2,400.00
  • Publishing Date: February 2018
  • Format: PDF
Sample Request

Eosinophilic Esophagitis Pipeline Analysis 2018 – Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments

Eosinophilic Esophagitis Pipeline Analysis report covers more than 10 drugs currently in different phases of development. Eosinophilic esophagitis (EOE) is a chronic allergic or immune condition where a person suffering with EOE tends to have inflammation of the esophagus. Esophagus is also known as food pipe which carries food from the mouth to the stomach. In the diseased state, a large number of white blood cells (WBCs) called eosinophils found in the food pipe. The symptoms vary with age, for toddlers, either they refuse to eat or do not grow properly; in case of school going children, they have recurring abdominal pain and also complain of trouble in swallowing or vomiting. Teenagers and adults have difficulty in swallowing dry or dense solid foods. There can be a condition where the food pipe can become too narrow to a point that food gets stuck known as food impaction and this calls for a medical emergency.

The report provides Eosinophilic Esophagitis treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.

Major industry players profiled as part of the report are AstraZeneca, Regeneron and Shire among others.


  • By Company
  • By Phase
  • By Molecule Type
  • By Region
  • By Route of Administration

* There may be changes in final report as per data availability.

1. Introduction
1.1. Research Methodology
1.2. Research Scope
1.2.1. Analysis by Company
1.2.2. Analysis by Phase
1.2.3. By Molecule Type
1.2.4. By region
2. Disease Overview
2.1.1. Introduction
2.1.2. Classification
2.1.3. Symptoms
2.1.4. Causes
2.1.5. Diagnoses
2.1.6. Treatment
2.1.7. Epidemiology
3. Executive Summary
4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities
5. Pipeline Analysis/Outlook
5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1. Phase of Development Introduction Drug Profiling
• Drug Name
• Generic Name
• Synonyms
• Company
• Collaborator
• Route of administration
• Target
• Mechanism of Action
• Technology
• Molecule type
• CAS Number
• Weight
• Chemical Formula
• IUPAC name
• ATC code Strategic Developments Clinical trials Clinical trial results Patents Technology
5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region
6. Company profiling
6.1. Regeneron Pharmaceuticals, Inc.
6.1.1. Introduction
6.1.2. Financials
6.1.3. Products and Services
6.1.4. SWOT
6.2. Adare Pharmaceuticals
6.2.1. Introduction
6.2.2. Financials
6.2.3. Products and Services
6.2.4. SWOT
6.3. Celgene Corporation
6.3.1. Introduction
6.3.2. Financials
6.3.3. Products and Services
6.3.4. SWOT
6.4. Calypso Biotech SA
6.4.1. Introduction
6.4.2. Financials
6.4.3. Products and Services
6.4.4. SWOT
6.5. Sanofi
6.5.1. Introduction
6.5.2. Financials
6.5.3. Products and Services
6.5.4. SWOT
6.6. Teva Pharmaceuticals Industries Ltd.
6.6.1. Introduction
6.6.2. Financials
6.6.3. Products and Services
6.6.4. SWOT
6.7. Shire
6.7.1. Introduction
6.7.2. Financials
6.7.3. Products and Services
6.7.4. SWOT
6.8. DBV Technologies
6.8.1. Introduction
6.8.2. Financials
6.8.3. Products and Services
6.8.4. SWOT
6.9. AstraZeneca
6.9.1. Introduction
6.9.2. Financials
6.9.3. Products and Services
6.9.4. SWOT
6.10. GlaxoSmithKline plc. (Dormant)
6.10.1. Introduction
6.10.2. Financials
6.10.3. Products and Services
6.10.4. SWOT
6.11. Biotica Pharmaceuticals.
6.11.1. Introduction
6.11.2. Financials
6.11.3. Products and Services
6.11.4. SWOT
6.12. Quorum Innovations
6.12.1. Introduction
6.12.2. Financials
6.12.3. Products and Services
6.12.4. SWOT
List of Tables
List of Figures
* There may be changes in final report as per data availability.

Related Reports
Back to the top